Immunotherapy for Type 1 Diabetes

描述(由申请人提供) 糖尿病预防试验的继续-1因为TrialNet将尝试 预防或延缓临床糖尿病的发病或保存残留的β细胞 在高危人群或新诊断疾病人群中发挥作用。这 是否会申请续展？洛杉矶S医院儿童医院 临床中心在TrialNet，并将完成糖尿病预防试验-1 协议。研究申请的具体目标将是确定是否 静脉注射免疫球蛋白(IVIG)(+)雷帕霉素4个月可保存 8-18岁新发病受试者的残余β细胞功能。残存的β细胞 功能将通过C-肽对混合餐耐受的反应来评估 测试。血糖控制和B、T标志物的次要结局指标 接下来将观察对β细胞抗原的细胞免疫反应。

DESCRIPTION (provided by applicant) The continuation of the Diabetes Prevention Trial-1 as TrialNet will attempt to prevent or delay the onset of clinical diabetes or preserve residual beta-cell function in populations at risk or in those with newly diagnosed disease. This application will be for the continuation of the Children?s Hospital Los Angeles Clinical Center in TrialNet and to complete the Diabetes Prevention Trial-1 protocol. The specific aims of the research application will be to determine if Intravenous Immunoglobulin (IVIG) (+) Rapamycin for 4 months can preserve residual beta-cell function in new onset subjects ages 8-18. Residual beta-cell function will be assessed by the C-peptide response to a Mixed Meal Tolerance Test. Secondary outcome measures of glycemic control and markers of the B and T cell immunologic response to beta-cell antigens will be followed.